According to Pacira Biosciences 's latest financial reports the company's current earnings (TTM) are $61.7 M. In 2022 the company made an earning of $13.3 M a decrease over its 2021 earnings that were of $56.4 M.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | $61.7 M | 363.85% |
2022 | $13.3 M | -76.42% |
2021 | $56.4 M | 180.76% |
2020 | $20.09 M | -286.92% |
2019 | -$10.75 M | 2428.94% |
2018 | -$0.43 M | -99% |
2017 | -$42.48 M | 12.23% |
2016 | -$37.85 M | -1885.05% |
2015 | $2.12 M | -115.65% |
2014 | -$13.55 M | -78.95% |
2013 | -$64.36 M | 21.55% |
2012 | -$52.94 M | 41.18% |
2011 | -$37.5 M | 57.4% |
2010 | -$23.83 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Zogenix ZGNX | -$0.22 B | -443.64% | ๐บ๐ธ USA |
Recro Pharma
REPH | $3.76 M | -93.90% | ๐บ๐ธ USA |
Omeros Corporation OMER | -$0.15 B | -343.10% | ๐บ๐ธ USA |
Flexion Therapeutics
FLXN | -$79.39 M | -228.67% | ๐บ๐ธ USA |
Heron Therapeutics HRTX | -$0.12 B | -279.19% | ๐บ๐ธ USA |
Cara Therapeutics
CARA | -$0.12 B | -291.10% | ๐บ๐ธ USA |